Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07463183) titled 'A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)' on March 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Merck Sharp & Dohme LLC
Condition:
Colitis Ulcerative
Ulcerative Colitis
Intervention:
Drug: MK-8690
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 30, 2026
Target Sample Size: 100
To know more, visit https://c...